Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Brainstorm Cell Therapeutics ($BCLI) reported positive results from a 48-subject Phase 2 study assessing NurOwn in patients with amyotrophic lateral sclerosis (ALS). The stock reacted positively to the news and touched $2.88 in Wednesday trading session. The stock closed at $2.62, up 21.86%.
The analyses of cerebral-spinal fluid from ALS patients treated with NurOwn showed statistically significant increases in levels of certain neurotrophic factors and statistically significant reductions in certain inflammatory markers over the same period compared to placebo.
The company also reported that a greater number of NurOwn-treated patients achieved 100% improvement in a functional rating scale called ALSFR-R versus placebo.

Pfizer Inc. ($PFE) reported negative results for its lead candidate XTANDI. The company stated that a Phase 4 study, PLATO, assessing XTANDI (enzalutamide), plus abiraterone [J&J's (NYSE:JNJ) Zytiga] and prednisone compared to abiraterone and prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (CRPC) failed to show an increase in efficacy with XTANDI as measured by progression-free survival.
Pfizer is collaborating with its commercialization partner Astellas Pharma ($ALPMF) for this project.
However, the company received the FDA approval for EUCRISA (crisaborole), a non-steroidal topical ointment for the treatment of mild-to-moderate atopic dermatitis (AD) in adults and children at least two years old.

 

• Merus Labs International ($MSLI) reported its fourth quarter sales at $34.3 million while its non-GAAP EBITDA for the same time period stood at $11.6 million. For 2017, the company expects its EBITDA to be in the range of $44 million and $48 million.

• The FDA has accepted Bayer's ($BAYRY) supplemental Biologics License Application (sBLA) seeking approval of the myBETApp and the BETACONNECT Navigator for review purpose.

• Intercept Pharmaceuticals ($ICPT) announced receiving condition approval from the European Commission for its Ocaliva (obeticholic acid), in combination with ursodeoxycholic acid (UDCA). The treatment is meant for primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, a chronic liver disease resulting from the progressive destruction of the bile ducts in the liver.

• CytomX Therapeutics ($CTMX) reported the FDA approval of its Investigational New Drug (IND) application for lead product candidate CX-072, a PD-L1-targeting Probody therapeutic for treating cancer.

 

• VistaGen Therapeutics ($VTGN) announced signing a sublicense agreement with BlueRock Therapeutics for VistaGen's rights to certain proprietary technologies related to the production of cardiac stem cells for the treatment of heart disease. Pursuant to the agreement, the company will receive an upfront payment of $1.25M, milestones and royalties on commercial sales.

• Organovo ($ONVO) announced entering into an exclusive distribution deal with Cosmo Bio Co., Ltd. for its NovoView Preclinical Services in Japan. CosmoBio will promote ONVO's liver and kidney tissue testing services to Japanese biopharmaceutical firms.

 
• ESSA Pharma ($EPIX) reported its fourth quarter loss at $4.2 million or $0.15 per share. For the entire year, the company lost $13.1 million or $0.49 per share. ESSA Pharma did not provide any guidance.

• Express Scripts ($ESRX) announced its outlook for 2017. The company expects its EBITDA to be in the range of $7.31 billion and $7.51 billion. For 2016, the company expects to earn between $5.28 and $5.34 per share, up from previous estimate of $4.47 and $4.53 per share range.

• Sarepta Therapeutics ($SRPT) receives price target cut from Jefferies. The new price target for the stock is $32, down from previous target of $46.

• Bruker ($BRKR) received rating downgrade from JPMorgan. The stock is now rated Neutral and its price target has been set at $20.

Gainers (% price change) Last Trade Change Mkt Cap
Antares Pharma Inc
ATRS (NASDAQ)
2.21 +0.17 (8.33%) 356.73M
China Cord Blood Corp
CO (NYSE)
5.30 +0.24 (4.74%) 441.34M
AMAG Pharmaceuticals, Inc
AMAG (NASDAQ)
36.05 +1.55 (4.49%) 1.25B
Zogenix, Inc.
ZGNX (NASDAQ)
11.70 +0.50 (4.46%) 277.66M
Array Biopharma Inc
ARRY (NASDAQ)
8.74 +0.34 (4.05%) 1.42B
Losers (% price change)
Immunomedics, Inc.
IMMU (NASDAQ)
3.73 -0.30 (-7.44%) 408.34M
Universal Health Services
UHS (NYSE)
101.55 -7.44 (-6.83%) 9.59B
Rockwell Medical Inc
RMTI (NASDAQ)
6.60 -0.44 (-6.25%) 312.15M
Sarepta Therapeutics Inc
SRPT (NASDAQ)
29.98 -1.84 (-5.78%) 1.64B
Bruker Corporation
BRKR (NASDAQ)
21.17 -1.25 (-5.58%) 3.46B
Most Actives (dollar volume)
Pfizer Inc.
PFE (NYSE)
32.82 +0.00 (0.00%) 201.81B
Johnson & Johnson
JNJ (NYSE)
114.99 -0.90 (-0.78%) 314.27B
Gilead Sciences, Inc.
GILD (NASDAQ)
75.71 +0.87 (1.16%) 101.60B
Universal Health Services
UHS (NYSE)
101.55 -7.44 (-6.83%) 9.59B
Bristol-Myers Squibb Co
BMY (NYSE)
58.50 +1.33 (2.33%) 98.84B